Fig. 8

Antitumor activity of Erastin on xenograft models. PC-9 LV OE-TNFSF11 and OE-NC cells were injected subcutaneously into the right flank of nude mice. Seven days after inoculation, mice received daily intraperitoneal Erastin (20 mg/kg) or vehicle control. (A, D, G, J) The tumor growth curves for mice in each treatment group. (B, E, H) Images of isolated tumors from nude mice at the endpoint. (C, F, I) Tumor weights in different groups. (K, L) Body weight of nude mice in each group during the treatment period. (M) Representative Hematoxylin and Eosin (HE) staining images of PC-9 LV OE-NC and PC-9 LV OE-TNFSF11 tumors. (N) Representative Immunohistochemistry images display the expression of TNFSF11 in PC-9 LV OE-NC and PC-9 LV OE-TNFSF11 tumors. (O, P, R) Western blot analysis of 4-HNE, caspase 3, caspase 9 in PC-9 LV OE-TNFSF11 tumors treated with DMSO or Erastin, α-Tubulin was used as a loading control. All results were repeated for three times. (Q) Relative 4-HNE expression levels between DMSO-treated and Erastin-treated PC-9 LV OE-TNFSF11 tumor groups, normalized to tubulin, Bars, means ± SD, n = 5. **P < 0.01. (S) Representative HE staining and Immunohistochemistry images of PC-9 LV OE-TNFSF11 tumors stained with 4-Hydroxynonenal (4-HNE) following treatment with DMSO or Erastin. 4-HNE: 4-Hydroxynonenal